Envarsus: first tablet presentation of tacrolimus

Chiesi has launched Envarsus, the first prolonged-release tablet formulation of tacrolimus. The once-daily tablets are available in 750 microgram, 1mg and 4mg strengths.

Like other oral tacrolimus products, Envarsus should be prescribed by brand name.
Like other oral tacrolimus products, Envarsus should be prescribed by brand name.

Further information
View Envarsus drug record
Manufacturer: Chiesi
MHRA advice on oral tacrolimus

Envarsus is licensed for the prevention of transplant rejection in kidney or liver allograft recipients and the treatment of allograft rejection resistant to other immunosuppressants.

Different formulations of tacrolimus are not interchangeable without careful monitoring. Healthcare professionals should be aware of the different bioavailabilities of the available oral formulations and take care to prescribe and dispense the correct product.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...

Updated bowel disease treatment summaries published by MIMS

Updated bowel disease treatment summaries published by MIMS

Updated quick-reference summaries of the latest NICE...